Clinical trials: Pathologic Neovascularization
Corneal Neovascularization
Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic Assessment
A Phase 1 randomized, double blinded, placebo-controlled, single dose escalation (SDE) and repeat dose escalation (RDE) study to evaluate safety and tolerability, and PK of KDR2-2 in healthy volunteers.
- Trial name
- NCT04620109
- Testing
- KDR2-2
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Guangzhou HuiBoRui Biological Pharmaceutical Technology Co. Ltd
Pathologic Myopia
High Myopia: Extended and Longterm Observation of Pathologic Myopia Patients With the Risk for Developing a Myopic Choroidal Neovascularization (CNV)
This research project intends to observe patients with high myopia who show pathological retinal changes, in order to evaluate more data on the risk factors for developing mCNV within this research project population in Germany.
- Trial name
- HELP (NCT03070717)
- Testing
- Observation & Diagnosis
- Where
- 26 sites in Germany
- Volunteers
- 153 people
- Sponsor
- Novartis Pharmaceuticals
Low-grade Glioma
Longitudinal MRI Assessment in Patients With Diffuse Low-grade Gliomas
Retrospective longitudinal follow-up in patients with diffuse low-grade glioma with multimodal MRI assessment
- Trial name
- SPECIFY (NCT04346472)
- Testing
- Repeated Measurements of the relative regional cerebral blood volume
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Montpellier
Pressure Ulcer, Bedsore
Correlation Between Pressure Differences and Micro-vascularization Changes in Bedridden Paraplegic Patient
Paraplegic patients have defective wound healing for sore below the level of spinal lesion. Defect of vascularization of the healing zone certainly participate to this effect.
- Conditions
- Pressure Ulcer, Bedsore, Spinal Cord Injury, Paraplegia
- Trial name
- VASCIP (NCT03114345)
- Testing
- Measurement of interface pressure, Measurement of micro-vascularization related parameters
- Where
- France
- Volunteers
- 4 people
- Sponsor
- University Hospital, Montpellier
Corneal Neovascularisation, Keratoconus
Investigation of Different Scanning Protocols for 3 Dimensional High-resolution Imaging of the Human Cornea With Optical Coherence Tomography (OCT) - A Pilot Study
The aim of the present study is to develop a protocol for optimal corneal 3-dimensional imaging based on measurements in healthy volunteers. For this purpose, a customized ultra-high resolution Spectral Domain OCT will be used.
- Trial name
- NCT01843101
- Testing
- Optical Coherence Tomography
- Where
- Austria
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration
Safety & Tolerability of the IRay System in Subjects With Exudative Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
The purpose of this study is to evaluate the safety and clinical feasibility of the IRay System for the treatment of wet age-related macular degeneration (AMD).
- Conditions
- Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration, Macular Degeneration, Eye Diseases
- Trial name
- NCT01217762
- Testing
- IRay
- Where
- Mexico
- Volunteers
- 62 people
- Sponsor
- Oraya Therapeutics, Inc.
Wet Age-related Macular Degeneration
Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration
GALATIR is a double blind randomized clinical trial comparing efficacy and safety of BCD-021 (bevacizumab) and Lucentis® (ranibizumab) in patients with neovascular wet age-related macular degeneration.
- Trial name
- GALATIR (NCT02036723)
- Testing
- Bevacizumab, Ranibizumab
- Where
- 13 sites in Brazil, Russia
- Sponsor
- Biocad
Macular Degeneration, Maculopathy, Age-Related
An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD
The purpose of this study is to demonstrate that anecortave acetate is superior to placebo in maintenance of visual acuity at the 12- and 24-month visits.
- Trial name
- NCT00058994
- Testing
- anecortave acetate
- Where
- United States
- Sponsor
- Alcon Research
Polypoidal Choroidal Vasculopathy
Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept
Polypoidal choroidal vasculopathy (PCV), a subtype of neovascular age-related macular degeneration (NV AMD), is an important cause of central visual loss, especially among Asian and African descendants.
- Trial name
- NCT04707027
- Testing
- Aflibercept Injection (2 mg/0.05 ml), Defer treatment
- Where
- Thailand
- Volunteers
- 80 people
- Sponsor
- Chiang Mai University
Choroidal Neovascularization
Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
The purpose of study is to determine if Lucentis combined with imatinib mesylate will help treatment in patients with newly diagnosed choroidal neovascularization.
- Trial name
- NCT00403156
- Testing
- Imatinib Mesylate /Ranibizumab
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Vitreous -Retina- Macula Consultants of New York
Central Serous Chorioretinopathy, Polypoidal Choroidal Vasculopathy
Angiographic Characteristics of CSC, PCV Patients and Thrombotic Bio-markers
Thrombotic biomarkers and angiographic characteristics were compared among the de novo patients of central serous chorioretinopathy (CSC), polypoidal choroidal vasculopathy (PCV) and the control.
- Trial name
- NCT02815176
- Testing
- Blood sampling
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Samsung Medical Center
Wet Macular Degeneration, Wet Age-related Macular Degeneration
Ziv-aflibercept Efficacy in Better Regulating AMD
This is a randomized, open-label, interventional, controlled study to determine the effects of Zaltrap on Neovascularized Wet Macular Degeneration as compared to the control anti-vascular endothelial growth factor ("anti-VEGF")…
- Trial name
- ZEBRA (NCT03423823)
- Testing
- Ziv-Aflibercept 25 MG/ML [Zaltrap], Ranibizumab
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Kapil Kapoor
Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization
Efficacy and Safety of RTH258 Versus Aflibercept - Study 1
The purpose of this study is to compare brolucizumab (RTH258) ophthalmic solution for intravitreal (IVT) injection at two dosage levels (3 mg and 6 mg) to aflibercept ophthalmic solution for IVT injection (2 mg) in subjects with…
- Trial name
- HAWK (NCT02307682)
- Testing
- Brolucizumab ophthalmic solution, Aflibercept ophthalmic solution
- Where
- United States
- Volunteers
- 1,775 people
- Sponsor
- Alcon Research
Myopic Choroidal Neovascularisation, Anti-VEGF Treatment
The Treatment Burden of Myopic Choroidal Neovascularization
Pathologic myopia (PM) is characterized by progressive eye elongation associated with degenerative changes in the retinal and choroidal tissue.
- Conditions
- Myopic Choroidal Neovascularisation, Anti-VEGF Treatment, Burden
- Trial name
- mCNV burden (NCT07009574)
- Testing
- anti-VEGF intravitreal treatment in patients affected by myopic choroidal neovascularization
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Policlinico Gaspare Rodolico - San Marco Catania
Retinal Neovascularization
Study of the Modification of the Retinal Nerve Fiber Layer in Patients Treated With Intravitreous Injection of Anti-VEGF
The intra-vitreous injection (IVT) of anti-VEGF (vascular endothelial growth factor) is currently the standard treatment for retinal neovascularization. The VEGF stimulates endothelial cells' proliferation and migration.
- Trial name
- IVT-RNFL (NCT02876198)
- Testing
- Gonioscopy
- Where
- 3 sites in France
- Volunteers
- 74 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Age Related Macular Degeneration
Foresee Home for Monitoring Age Related Macular Degeneration (AMD)
The FORESEE HOME is intended for the early detection of central and paracentral irregularities (abnormalities) in the visual field, most commonly associated with AMD.
- Trial name
- Foresee Home (NCT01010997)
- Testing
- Foresee Home
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Notal Vision Ltd.
Macular Degeneration
Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration
The purpose of this study is to confirm the efficacy and safety of rostaporfin (PHOTREX) photodynamic therapy (PDT) in the treatment of classic and occult subfoveal choroidal neovascularization (CNV) associated with age-related…
- Trial name
- NCT00157976
- Testing
- Photrex (rostaporfin)
- Where
- 4 sites in Bulgaria, Czechia and 2 more
- Volunteers
- 660 people
- Sponsor
- Miravant Pharmaceuticals
Hepatocellular Carcinoma
Bevacizumab in Advanced Hepatocellular Carcinoma
Primary liver cancer (hepatocellular carcinoma) is the fifth most common malignant disorder, with an increasing incidence in Europe and the USA as a result of the high prevalence of hepatitis C.
- Trial name
- NCT00162669
- Testing
- bevacizumab
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Choroidal Neovascularization, Visual Field, Visual Acuity
OCT and Microperimetry in Patients With Active Neovascular ARMD (CORFI)
ARMD is the main cause of visual disability after 50 years old in France. Patients with active neovascular ARMD are treated with intravitreal injections of antiVEGF.
- Trial name
- CORFI (NCT03435926)
- Where
- France
- Sponsor
- University Hospital, Limoges
Macular Degeneration
Identification and Treatment of Feeder Vessels in Macular Degeneration
This study will try to identify and treat feeder vessels in age-related macular degeneration. The macula is the part of the retina in the back of the eye that determines central or best vision.
- Trial name
- NCT00018070
- Testing
- Angiography, Laser Treatment
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Eye Institute (NEI)